
CUDC-427
CAS No. 1446182-94-0
CUDC-427( —— )
Catalog No. M33326 CAS No. 1446182-94-0
CUDC-427 (GDC-0917) is an orally bioactive and pan antagonist of inhibitor of apoptosis proteins(IAPs). CUDC-427 can be used in research on cancers.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 64 | Get Quote |
![]() ![]() |
5MG | 93 | Get Quote |
![]() ![]() |
10MG | 155 | Get Quote |
![]() ![]() |
25MG | 266 | Get Quote |
![]() ![]() |
50MG | 381 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCUDC-427
-
NoteResearch use only, not for human use.
-
Brief DescriptionCUDC-427 (GDC-0917) is an orally bioactive and pan antagonist of inhibitor of apoptosis proteins(IAPs). CUDC-427 can be used in research on cancers.
-
DescriptionCUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.
-
In VitroGDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80% inhibition at concentrations greater than 0.1 μM (56.5 ng/mL).
-
In VivoGDC-0917 (0.08-16.3 mg/kg) exhibits antitumor activity in a dose dependent manner in the MDA-MB-231-X1.1 Breast Cancer Xenograft, and GDC-0917 is well tolerated, with all dose groups experiencing a <11% decrease in mean body weight. GDC-0917 has low to moderate clearance in the mouse (12.0 mL/min/kg), rat (27.0 mL/min/kg), and dog (15.3 mL/min/kg), and high clearance in the monkey (67.6 mL/min/kg). Oral bioavailability is lowest in monkeys compared with other species.
-
Synonyms——
-
PathwayApoptosis
-
TargetIAP
-
RecptorIAP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1446182-94-0
-
Formula Weight564.7
-
Molecular FormulaC29H36N6O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (88.54 mM; Ultrasonic )
-
SMILESCN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wong H, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos. 2013 Dec;41(12):2104-13.?
molnova catalog



related products
-
BV6
A small molecule, bivalent IAP antagonist that binds to the c-IAP1 and XIAP BIR2-BIR3 domains.
-
Birinapant
Birinapant is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM, less potent to XIAP. Phase 2.
-
MX106
MX106 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 2.2 uM.